Observation of Italian Patients with Heart Failure Being Treated with Dapagliflozin in Clinical Practice - EVOLUTION-HF

Study identifier:D1699R00030

ClinicalTrials.gov identifier:NCT05250011

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Early Treatment of Heart Failure: a Non-Interventional Observational Study of Italian Patients with Heart Failure and Initiated on Dapagliflozin

Medical condition

Heart Failure, Reduced Ejection Fraction

Phase

N/A

Healthy volunteers

No

Study drug

Dapagliflozin

Sex

All

Actual Enrollment

252

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 19 Apr 2022
Primary Completion Date: 15 Apr 2024
Study Completion Date: 15 Apr 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Fullcro s.r.l.

Inclusion and exclusion criteria